Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Caravel Bio secures $1.2M NSF Phase II grant to advance biomolecular engineering platform for protein design with new-to-nature chemistries.
Nov 04, 2026
PortlandBiotechnology
Description
Caravel Bio, a Portland, OR-based biomolecular engineering platform provider, received a $1.2M NSF Phase II grant. The funds will support development of a system for creating and scaling proteins with new-to-nature chemistries, scaling machine learning datasets, and extending the platform to additional enzyme classes. The company will execute real-world pilots for customers in DNA writing, carbon capture, and rare earth separations. Caravel Bio's platform combines cell-free protein synthesis, microfluidic droplets, and bacterial spore display to enable discovery and design of novel proteins.
Company Information
Company
Caravel Bio
Location
Portland, Oregon, United States
About
Caravel Bio is a Portland, OR-based provider of a biomolecular engineering and protein design platform that combines cell-free protein synthesis, microfluidic droplets, and bacterial spore display. The company develops machine learning models and lab workflows to expand the amino acid palette beyond conventional amino acids, enabling discovery and design of novel proteins. Their platform is applied to applications in medicine, environmental remediation, and industrial biotechnology, including DNA writing, carbon capture, and rare earth separations.
Predictive Intelligence
Strategic
ML-powered predictions for Caravel Bio's next move
PortlandBiotechnology